Phase 2 N=30 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)
Penile Cancer
Primary: Objective Response Rate (ORR) — 3; 15 Participants
N/A N=718 The Prevent Anal Cancer Palpation Study
Anal Cancer
Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
N/A N=82 Penile Length Maintenance Post-Prostatectomy
Prostate Cancer · Penile Diseases
Primary: Change in Penile Length — 0.3; 1.6 centimeters
N/A N=609 Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination
Anus Neoplasms
Primary: Willingness to Receive the Human Papillomavirus (HPV) Vaccine — 338 Participants
Phase 2 N=12 H-22411: BOTOX® for Peyronie's Disease
Peyronie's Disease
Primary: Average Percent Change of Penile Curvature in Degrees — -21.73; 2.429 percent change — p=0.5154
Phase 2 N=135 Vessel Sparing Prostate Radiation Therapy
Cancer of the PROSTATE
Primary: The Percentage of Patients Able to be Sexually Active With or Without the Use of Aids — 88 percentage of patients
N/A N=178 Sexual Function and Wellbeing in Males With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014
Phase 3 N=52 Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
Malignant Neoplasms of Male Genital Organs
Primary: Post-Operative Pain Medication Usage in Post Anesthesia Care Unit (PACU) — 13.0208; 15.1786 mg
N/A N=240 The Prevent Anal Cancer Self-Swab Study
Anal Cancer
Primary: Compliance With Annual Anal HPV DNA Screening — 107; 89; 13; 31 Participants
N/A N=200 Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men
Human Papillomavirus
Primary: HPV Prevalence — 61 participants
Phase 3 N=1,589 Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Preneoplastic Conditions · Prostatic Intraepithelial Neoplasia
Primary: Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) — 54.9; 59.5 % of participants cancer-free…
Phase 2 N=32 Pembrolizumab in Metastatic Anal Cancer
Anal Cancer
Primary: Overall Response Rate — 11.1 probability
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
N/A N=1,459 Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
Priapism · Anemia, Sickle Cell
Primary: Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia. — 18; 58; 160; 189 participants
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
N/A N=110 Penile Length Restoration in Men With Diabetes Mellitus, Type II
Diabetes Mellitus, Type 2 · Penile Diseases
Primary: Penile Length Change Between Baseline and Month 6 — 0; 0.5; 0.5; 0.8 Median change from baseline (cm)
N/A N=140 Prostate Cancer - Patient Empowerment Program
Prostate Cancer
Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
Phase 2 N=48 E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
N/A N=40 Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)
Erectile Dysfunction
Primary: The Study's Primary Objective Will Assess the Change in Penile Length. — 1.14; 0.99; 1.04; 0.94 cm
N/A N=110 Efficacy of Penile Traction Therapy Using a Novel Device
Penile Diseases
Primary: Adverse Events at Baseline — 2; 2; 1; 7 percentage of participants
N/A N=403 Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
Prostatic Neoplasm
Primary: Urinary Function Scores — 80.1; 81.4 Scores on a scale (0-100)
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Phase 3 N=242 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
Prostate Cancer · Sexual Dysfunction
Primary: Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT) — 79; 74 percentage of…
N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
Phase 2 N=11 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Cancer of Head and Neck · Cancer of Cervix · Cancer of Anus
Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants